Ligand Pharmaceuticals Incorporated
LGND
株式のランク
#3096
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
株価
$291.18
最終同期: 2026-07-31
時価総額
$5.84B
変化（1日）
-1.73%
変化（1年）
55.99%
国
US
取引 Ligand Pharmaceuticals Incorporated (LGND)
カテゴリー
Healthcare
Ligand Pharmaceuticals Incorporated（LGND）の収益
Jun 2026 時点の収益 TTM: $290.54M
Ligand Pharmaceuticals Incorporated の最新の財務報告によると、現在の収益 (TTM) は $290.54M です。2023 年には $131.31M の収益があり、これは 2022 年の $196.25M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Ligand Pharmaceuticals Incorporated の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $290.54M | 73.84% |
| 2024 | $167.13M | 27.28% |
| 2023 | $131.31M | -33.09% |
| 2022 | $196.25M | -18.75% |
| 2021 | $241.54M | 47.68% |
| 2020 | $163.56M | 35.98% |
| 2019 | $120.28M | -52.17% |
| 2018 | $251.45M | 78.21% |
| 2017 | $141.10M | 29.48% |
| 2016 | $108.97M | 51.53% |
| 2015 | $71.91M | 11.43% |
| 2014 | $64.54M | 31.78% |
| 2013 | $48.97M | 56.03% |
| 2012 | $31.39M | 4.50% |
| 2011 | $30.04M | 27.61% |
| 2010 | $23.54M | -39.55% |
| 2009 | $38.94M | 42.56% |
| 2008 | $27.32M | 111.84% |
| 2007 | $12.89M | -90.85% |
| 2006 | $140.96M | -20.18% |
| 2005 | $176.61M | 8.01% |
| 2004 | $163.51M | 15.85% |
| 2003 | $141.14M | 46.05% |
| 2002 | $96.64M | 26.59% |
| 2001 | $76.34M | 58.68% |
| 2000 | $48.11M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 4,245.09% |
US
|
|
| $2.23B | 666.84% |
US
|
|
| $15.74B | 5,318.95% |
AU
|
|
| $6.02B | 1,972.43% |
NL
|
|
| - | - |
CH
|
